Your browser is no longer supported. Please, upgrade your browser.
HZNP Horizon Therapeutics Public Limited Company monthly Stock Chart
HZNP [NASD]
Horizon Therapeutics Public Limited Company
Index- P/E15.68 EPS (ttm)2.03 Insider Own0.90% Shs Outstand196.16M Perf Week12.15%
Market Cap6.25B Forward P/E12.98 EPS next Y2.45 Insider Trans-24.21% Shs Float188.11M Perf Month-13.52%
Income573.00M PEG1.16 EPS next Q0.21 Inst Own91.50% Short Float3.20% Perf Quarter-12.45%
Sales1.30B P/S4.81 EPS this Y712.30% Inst Trans2.59% Short Ratio3.49 Perf Half Y21.38%
Book/sh11.76 P/B2.71 EPS next Y30.95% ROA14.50% Target Price44.70 Perf Year18.05%
Cash/sh5.49 P/C5.80 EPS next 5Y13.50% ROE33.90% 52W Range22.69 - 39.10 Perf YTD-12.02%
Dividend- P/FCF15.30 EPS past 5Y23.60% ROI18.70% 52W High-18.54% Beta1.03
Dividend %- Quick Ratio2.30 Sales past 5Y34.40% Gross Margin72.10% 52W Low40.37% ATR2.36
Employees1200 Current Ratio2.30 Sales Q/Q2.30% Oper. Margin5.20% RSI (14)56.18 Volatility7.02% 8.22%
OptionableYes Debt/Eq0.00 EPS Q/Q458.70% Profit Margin44.10% Rel Volume1.25 Prev Close30.19
ShortableYes LT Debt/Eq0.62 EarningsFeb 26 BMO Payout0.00% Avg Volume1.72M Price31.85
Recom1.70 SMA2010.28% SMA50-3.16% SMA2007.00% Volume2,158,281 Change5.48%
Jan-08-20Initiated Goldman Neutral $35
Sep-26-19Initiated BofA/Merrill Buy $34
Sep-12-19Initiated Guggenheim Buy
Aug-14-19Upgrade BMO Capital Markets Market Perform → Outperform $29 → $36
May-01-19Upgrade Citigroup Neutral → Buy $21 → $32
Mar-08-19Upgrade Morgan Stanley Equal-Weight → Overweight $32
Nov-15-18Downgrade Mizuho Buy → Neutral
Jun-27-18Downgrade Citigroup Buy → Neutral
Jan-12-18Upgrade Mizuho Neutral → Buy $12 → $18
Sep-28-17Initiated Goldman Buy $16
Jun-16-17Initiated Cantor Fitzgerald Overweight $13
May-09-17Reiterated Stifel Buy $35 → $20
May-09-17Downgrade Mizuho Buy → Neutral $22 → $10
Feb-28-17Reiterated Mizuho Buy $25 → $22
Dec-16-16Upgrade Mizuho Neutral → Buy $14 → $25
Dec-09-16Downgrade Mizuho Buy → Neutral $30 → $14
Nov-28-16Upgrade Citigroup Neutral → Buy
Nov-08-16Reiterated Mizuho Buy $29 → $30
Oct-31-16Reiterated Mizuho Buy $33 → $29
Sep-13-16Reiterated Mizuho Buy $30 → $33
Apr-02-20 08:00AM  Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate to Expand Development-Stage Pipeline Business Wire +5.48%
Mar-31-20 12:00PM  TEPEZZA (teprotumumab-trbw) Significantly Reduces Proptosis (Eye Bulging), a Key Marker of Thyroid Eye Disease, Across Patient Subtypes Business Wire
08:00AM  Why These 7 Pharma Stocks Are Outplaying 90% Of The Stock Market Investor's Business Daily
Mar-26-20 04:15PM  Horizon Therapeutics plc Donates $1.5 Million to COVID-19 Response Efforts in Illinois and Other Impacted U.S. and Global Communities Business Wire
Mar-22-20 10:13PM  Should You Buy Horizon Pharma Public Limited Company (HZNP)? Insider Monkey
Mar-18-20 08:01AM  Should You Worry About Horizon Therapeutics Public Limited Company's (NASDAQ:HZNP) CEO Salary Level? Simply Wall St. -6.94%
Mar-17-20 02:04PM  Top Pharmaceutical Stocks for Q2 2020 Investopedia
Mar-03-20 08:00AM  Horizon Therapeutics plc Launches the Down and Out Kidney Campaign to Call Attention to the Prevalence and Impact of Gout in Chronic Kidney Disease Business Wire
Feb-28-20 10:00AM  Horizon and Willis Tower Elevate the Need for Rare Disease Innovation on Rare Disease Day Business Wire
08:00AM  Horizon Therapeutics plc Partners with EveryLife Foundation to Establish $1 Million #RAREis Scholarship for Adults with Rare Diseases Business Wire
Feb-27-20 08:00AM  Horizon Therapeutics plc Named One of the Best Workplaces in Ireland Business Wire
03:10AM  Edited Transcript of HZNP earnings conference call or presentation 26-Feb-20 1:00pm GMT Thomson Reuters StreetEvents
Feb-26-20 07:00AM  Horizon Therapeutics plc Reports Fourth-Quarter and Full-Year 2019 Financial Results; Announces Full-Year 2020 Guidance Business Wire
Feb-18-20 08:30AM  Horizon Therapeutics plc to Present at the Cowen and Company 40th Annual Health Care Conference Business Wire
08:00AM  Horizon Therapeutics plc Announces U.S. FDA Approval of New Dosage Form for PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Oral Granules Business Wire
Feb-11-20 08:00AM  Uplifting Athletes Announces Horizon Therapeutics plc as Exclusive Sponsor to Help Tackle Rare Disease at the National Football League (NFL) Scouting Combine Business Wire
Feb-06-20 10:51AM  Allergan (AGN) to Report Q4 Earnings: What's in the Cards? Zacks
Feb-04-20 10:19AM  What's in Store for Innoviva (INVA) This Earnings Season? Zacks
08:00AM  Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2019 Financial Results and Host Webcast on Feb. 26, 2020 Business Wire
Jan-28-20 11:10AM  Horizon Therapeutics Announces Significant Expansion and Relocation of U.S. Operations Business Wire
Jan-27-20 12:10PM  Why the Earnings Surprise Streak Could Continue for Horizon Therapeutics (HZNP) Zacks
Jan-24-20 04:05PM  Horizon Therapeutics plc Announces Changes in Research and Development Organization Business Wire
Jan-23-20 11:40AM  REGN vs. HZNP: Which Stock Is the Better Value Option? Zacks
Jan-22-20 05:20PM  The New England Journal of Medicine Publishes Comprehensive Data from Phase 3 Clinical Trial (OPTIC) of TEPEZZA (teprotumumab-trbw) for Thyroid Eye Disease Business Wire
10:03AM  Horizon Therapeutics Gets FDA Approval for Eye Drug Tepezza Zacks
09:45AM  Biotech Stock Roundup: Updates From HZNP & CLVS, BioNTech to Acquire Neon Zacks
Jan-21-20 03:04PM  FDA Approves TEPEZZATM (teprotumumab-trbw) for the Treatment of Thyroid Eye Disease (TED) Business Wire
02:59PM  FDA approves Horizon's drug for thyroid eye disease Reuters
Jan-18-20 09:08AM  Are Investors Undervaluing Horizon Therapeutics Public Limited Company (NASDAQ:HZNP) By 37%? Simply Wall St.
Jan-15-20 05:00AM  Top Picks 2020- Horizon Therapeutics HZNP and Qorvo QRVO MoneyShow
Jan-14-20 07:55AM  The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug Benzinga
Jan-13-20 08:15AM  Horizon Therapeutics plc Increases Peak U.S. Annual Net Sales Expectations for Key Growth Drivers; Provides Update on Several Pipeline Programs Business Wire
08:05AM  MIRROR Open-Label Study Topline Data of Methotrexate with KRYSTEXXA (pegloticase injection) Indicates Significant Improvement in Response Rate Business Wire
Jan-03-20 09:58AM  Horizon Therapeutics' Stock Up in a Year on Pipeline Progress Zacks
Jan-02-20 08:34AM  3 Healthcare Stocks Primed for 2020 Gains TipRanks
Dec-26-19 10:56AM  How Did Horizon Pharma Public Limited Company (HZNP) Compare Against Top Hedge Fund Stocks in 2019? Insider Monkey
Dec-20-19 11:40AM  ALXN vs. HZNP: Which Stock Should Value Investors Buy Now? Zacks
Dec-16-19 09:46AM  Horizon Therapeutics Eye Drug Gets Positive FDA Advisory Vote Zacks
08:40AM  Horizon's stock jumps on FDA adcomm support for eye drug MarketWatch
Dec-13-19 04:01PM  FDA Advisory Committee Votes Unanimously to Support the Use of Teprotumumab for the Treatment of Thyroid Eye Disease (TED) Business Wire
07:11AM  Horizon Therapeutics halted for FDA advisory committee meeting on treatment for thyroid eye disease MarketWatch
07:00AM  Horizon Therapeutics plc Trading Halted Today; FDA Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) Meeting to Discuss Teprotumumab for Thyroid Eye Disease Business Wire
Dec-09-19 08:00AM  Horizon Therapeutics plc to Present at the 38th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-06-19 11:31AM  Why Is Horizon Therapeutics (HZNP) Up 7.5% Since Last Earnings Report? Zacks
Dec-04-19 11:27AM  Should We Be Cautious About Horizon Therapeutics Public Limited Company's (NASDAQ:HZNP) ROE Of 3.0%? Simply Wall St.
Dec-03-19 10:04AM  Here is What Hedge Funds Think About Horizon Pharma Public Limited Company (HZNP) Insider Monkey
Nov-25-19 09:35AM  How location, focus and CEO's own rare-disease diagnosis is driving this drug company American City Business Journals
Nov-24-19 06:29PM  S&P 500: Winning Streak Ends TipRanks
Nov-22-19 08:00AM  Horizon Therapeutics plc Opens New Manufacturing and R&D Facility in South San Francisco Business Wire
Nov-21-19 08:00AM  Horizon Therapeutics plc Launches New Online Community Connecting People Living with Thyroid Eye Disease and Urging them to Listen to Your Eyes Business Wire
Nov-14-19 09:30AM  FORTUNE and Great Place to Work® Name Horizon Therapeutics plc to Best Workplaces for Parents List Business Wire
Nov-13-19 04:15PM  Horizon Therapeutics plc to Participate in Upcoming Investor Conferences Business Wire
Nov-11-19 02:05PM  Edited Transcript of HZNP earnings conference call or presentation 6-Nov-19 1:00pm GMT Thomson Reuters StreetEvents
08:00AM  Data from Uncontrolled Gout Case Series Supports Immunomodulation with KRYSTEXXA® (pegloticase injection) Strategy to Optimize Treatment Outcomes Business Wire
05:57AM  3 Market-Beating Stocks for Your 2020 Radar TipRanks
Nov-08-19 10:02AM  After sons rare disease diagnosis, father finds hope through film festival American City Business Journals
09:30AM  The Chicago Tribune Names Horizon Therapeutics plc a 2019 Top Workplace Business Wire
Nov-07-19 11:05AM  Horizon Therapeutics' (HZNP) Q3 Earnings Beat Estimates Zacks
Nov-06-19 08:45AM  Horizon Therapeutics (HZNP) Q3 Earnings and Revenues Beat Estimates Zacks
07:00AM  Horizon Therapeutics plc Reports Strong Third-Quarter 2019 Results Business Wire
Nov-05-19 08:00AM  Horizon Therapeutics plc Brings Gout-Kidney Link into Focus during American Society of Nephrology (ASN) Kidney Week 2019 Business Wire
Nov-04-19 08:30AM  Clinical Study Data Highlighting the Impact of Teprotumumab in Patients With Active Thyroid Eye Disease to Be Presented During ACR Annual Meeting Business Wire
08:00AM  New Evidence on the Burden of Gout to be Featured in Data Presentations at Upcoming ACR Annual Meeting Business Wire
Oct-31-19 10:00AM  Integrated Clinical Trial Analyses Further Substantiate that Teprotumumab Significantly Improves Debilitating Effects of Thyroid Eye Disease, Including Eye Bulging, Double Vision and Quality of Life Business Wire
Oct-30-19 10:33AM  Analysts Estimate Horizon Therapeutics (HZNP) to Report a Decline in Earnings: What to Look Out for Zacks
Oct-24-19 11:15AM  Horizon Therapeutics plc Named One of the Most Innovative Companies by Crains Chicago Business Business Wire
09:30AM  HZNP or BMRN: Which Is the Better Value Stock Right Now? Zacks
08:00AM  New Combined Data from the Phase 2 and Phase 3 Teprotumumab Clinical Trials to be Presented during the American Thyroid Association Annual Meeting Business Wire
Oct-17-19 04:48PM  Did Hedge Funds Drop The Ball On Horizon Therapeutics Public Limited Company (HZNP) ? Insider Monkey
09:00AM  FORTUNE and Great Place to Work® Name Horizon Therapeutics plc to Best Small & Medium Workplaces List for Fourth Consecutive Year Business Wire
08:41AM  Is Horizon Therapeutics's (NASDAQ:HZNP) 128% Share Price Increase Well Justified? Simply Wall St.
08:00AM  Horizon Therapeutics plc Initiates PROTECT Trial Evaluating KRYSTEXXA® (pegloticase injection) to Improve Management of Uncontrolled Gout for Adults with a Kidney Transplant Business Wire
Oct-16-19 03:23PM  Four stocks that are nearing key breakouts MarketWatch
11:51AM  4 Stocks Nearing Key Breakouts Benzinga
Oct-11-19 12:30PM  New Data from Teprotumumab Phase 3 OPTIC Study Shows Significantly Reduced Double Vision and Improved Quality of Life for People with Active Thyroid Eye Disease Business Wire
Oct-10-19 09:00AM  For World Sight Day, Horizon and Prevent Blindness Are Calling on the Thyroid Eye Disease (TED) Community to Put Vision First Business Wire
Oct-09-19 08:00AM  Horizon Therapeutics plc to Release Third-Quarter 2019 Financial Results and Host Webcast on Nov. 6, 2019 Business Wire
Oct-08-19 08:00AM  New Data Insights from the Phase 3 Teprotumumab Trial (OPTIC) to be Presented at the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) Scientific Symposium Business Wire
Oct-03-19 08:00AM  Horizon Therapeutics plc Named One of the Best Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption Business Wire
Sep-12-19 10:02AM  Horizon (HZNP) Up 36.7% YTD: Pipeline Development in Focus Zacks
Sep-11-19 10:49AM  Biotech Stock Roundup: AMGN's Lung Cancer Candidate, ALXN's Deal With Eidos in Focus Zacks
Sep-10-19 04:13PM  Is Nancy Pelosi's Drug-Pricing Plan Feasible Or Is It A Political Ploy? Investor's Business Daily
07:59AM  Horizon's (HZNP) Eye Disease Drug Gets FDA's Priority Review Zacks
Sep-09-19 08:00AM  Horizon Therapeutics plc Announces the FDA has Granted Priority Review of the Teprotumumab Biologics License Application (BLA) for the Treatment of Active Thyroid Eye Disease (TED) Business Wire
Sep-06-19 09:31AM  Why Is Horizon Therapeutics (HZNP) Down 3.3% Since Last Earnings Report? Zacks
Sep-02-19 10:28AM  Is Horizon Therapeutics (NASDAQ:HZNP) Using Too Much Debt? Simply Wall St.
Aug-28-19 04:30PM  Horizon Therapeutics plc Names Andy Pasternak Executive Vice President, Chief Business Officer Business Wire
Aug-23-19 06:15PM  Horizon Therapeutics Plc (HZNP) Chairman, President and CEO Timothy P Walbert Sold $1. ... GuruFocus.com
Aug-19-19 09:00AM  American Journal of Ophthalmology (AJO) Publishes Review Highlighting Lack of Treatments for Active Thyroid Eye Disease (TED) Business Wire
08:00AM  Horizon Therapeutics plc to Participate in the Morgan Stanley 17th Annual Global Healthcare Conference Business Wire
Aug-14-19 10:47AM  Horizon Therapeutics Has 'Headroom For Value Creation,' BMO Says In Upgrade Benzinga
08:00AM  Horizon Therapeutics plc Collaborates with Rare Disease Advocates to Elevate Resources and Shared Experiences Through Launch of #RAREis Community Website Business Wire
Aug-13-19 11:24AM  Canadian drug price regulator may be flexible on rare diseases Reuters
Aug-12-19 07:15PM  Horizon Therapeutics Plc (HZNP) EVP, Corporate Affairs, CCO Geoffrey M. ... GuruFocus.com
Aug-08-19 10:15AM  Horizon Therapeutics' (HZNP) Q2 Earnings Beat Estimates Zacks
Aug-07-19 04:31PM  Horizon Stock Pops On Beat And Raise As Another Drugmaker Reverses Investor's Business Daily +12.01%
03:23PM  Horizon Pharma PLC (HZNP) Q2 2019 Earnings Call Transcript Motley Fool
08:45AM  Horizon Therapeutics (HZNP) Surpasses Q2 Earnings and Revenue Estimates Zacks
07:00AM  Horizon Therapeutics plc Reports Strong Second-Quarter 2019 Results; Increases FullYear 2019 Net Sales and Adjusted EBITDA Guidance Business Wire
Aug-06-19 10:00AM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. The company's primary care marketed medicines comprise PENNSAID 2% that is indicated for the treatment of pain of osteoarthritis of the knees; DUEXIS for the relief of signs and symptoms of RA and OA, and to decrease the risk of developing upper-GI ulcers; VIMOVO for the relief of signs and symptoms of OA, RA, and AS and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and MIGERGOT, a therapy to abort or prevent vascular headaches, such as migraines and migraine variants. It has collaboration agreements with Alliance for Lupus Research, Syneos Health, Inc., and HemoShear Therapeutics, LLC. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MOZE BARRYEVP, Chief Admin. OfficerMar 30Option Exercise12.942,10627,252168,397Mar 31 05:01 PM
MOZE BARRYEVP, Chief Admin. OfficerMar 30Sale28.182,10659,347166,291Mar 31 05:01 PM
SHERMAN JEFFREY WEVP and Chief Medical OfficerMar 11Option Exercise12.945,28768,41413,966Mar 13 04:15 PM
McHugh Miles WSr VP & Princ. Acctg OfficerFeb 27Sale34.341,00034,3420Feb 28 05:00 PM
Walbert Timothy PChairman, President and CEOFeb 21Sale35.2393,8643,306,829847,743Feb 21 08:07 PM
Walbert Timothy PChairman, President and CEOFeb 01Option Exercise0.009,086011,818Feb 04 04:14 PM
Kent JeffSee remarksJan 07Sale36.503,545129,393111,667Jan 07 06:30 PM
Karnani VikramEVP, Chief Commercial OfficerJan 06Sale35.629,297331,15978,146Jan 07 06:23 PM
Walbert Timothy PChairman, President and CEOJan 06Sale35.5784,8863,019,395903,309Jan 07 06:18 PM
Beeler Brian KEVP, General CounselDec 18Sale35.006,716235,06077,917Dec 20 04:46 PM
Beeler Brian KEVP, General CounselNov 25Sale32.519,969324,09384,633Nov 27 04:18 PM
McHugh Miles WSr VP & Princ. Acctg OfficerNov 14Option Exercise22.144,51699,984127,096Nov 15 04:19 PM
Beeler Brian KEVP, General CounselNov 05Sale30.0212,475374,46294,602Nov 07 04:38 PM
Walbert Timothy PChairman, President and CEOOct 15Option Exercise5.82311,8691,814,8791,097,165Oct 17 04:41 PM
Hoelscher Paul W.EVP, CFOOct 15Sale28.0120,000560,100139,310Oct 17 04:42 PM
Walbert Timothy PChairman, President and CEOOct 15Sale28.02320,1748,970,283776,991Oct 17 04:41 PM
Shannon James SamuelDirectorSep 13Option Exercise12.199,500115,8059,500Sep 13 06:52 PM
Shannon James SamuelDirectorSep 13Sale26.199,500248,8050Sep 13 06:52 PM
Shannon James SamuelDirectorSep 12Option Exercise12.1915,500188,94515,500Sep 13 06:52 PM
Shannon James SamuelDirectorSep 12Sale26.5915,500412,1310Sep 13 06:52 PM
Konstantinovsky IrinaEVP, Chief Human Resources OffSep 12Sale26.7017,838476,27519,886Sep 13 06:51 PM
Hoelscher Paul W.EVP, CFOAug 30Sale28.001,35938,052159,310Sep 04 05:41 PM
Walbert Timothy PChairman, President and CEOAug 30Sale28.002,50070,000785,296Sep 04 05:34 PM
Hoelscher Paul W.EVP, CFOAug 22Option Exercise16.9029,576499,942160,669Aug 23 04:58 PM
Walbert Timothy PChairman, President and CEOAug 22Sale28.001,98455,552787,796Aug 23 04:57 PM
Hoelscher Paul W.EVP, CFOAug 21Sale28.0070,9031,985,426131,093Aug 23 04:58 PM
Walbert Timothy PChairman, President and CEOAug 21Sale28.0056,8361,591,518789,780Aug 23 04:57 PM
CURTIS GEOFFREY M.EVP, Corporate Affairs, CCOAug 08Sale26.5820,609547,83028,382Aug 12 04:58 PM
Kent JeffSee remarksAug 05Sale23.8411,140265,540107,115Aug 05 04:59 PM
Karnani VikramEVP, Chief Commercial OfficerJul 01Sale25.0213,111327,98057,412Jul 03 04:06 PM